Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | GPR139 | Q6DWJ6 | 8/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2693400 | 1.00 | TRPV1 (1.00) | TRPV1MAPK1GPR139ENPP2ALDH1A1 | |
| SCHEMBL30005521 | 1.00 | TRPV1 (1.00) | TRPV1MAPK1GPR139ENPP2ALDH1A1 | |
| SCHEMBL14292204 | 0.92 | TRPV1 (0.85) | TRPV1MAPK1GPR139ENPP2ALDH1A1 | |
| SCHEMBL2692812 | 0.92 | TRPV1 (0.85) | TRPV1MAPK1GPR139ENPP2 | |
| SCHEMBL4492187 | 0.91 | TRPV1 (0.83) | TRPV1MAPK1GPR139ENPP2ALDH1A1 | |
| SCHEMBL308087 | 0.90 | TRPV1 (0.82) | TRPV1MAPK1GPR139ENPP2ALDH1A1 | |
| SCHEMBL307997 | 0.90 | TRPV1 (0.82) | TRPV1MAPK1GPR139ENPP2ALDH1A1 | |
| SCHEMBL307996 | 0.90 | TRPV1 (0.82) | TRPV1MAPK1GPR139ENPP2ALDH1A1 | |
| SCHEMBL5133535 | 0.88 | TRPV1 (0.79) | TRPV1MAPK1ENPP2 | |
| SCHEMBL306685 | 0.88 | TRPV1 (0.78) | TRPV1MAPK1GPR139ENPP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168668-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-05-01 | — | — | US | claimed |
| EP-1966156-B1 | NEW COMPOUNDS III | ASTRAZENECA AB (SE) | 2011-12-21 | — | — | EP | claimed |
| US-20100286202-A1 | New Compounds | ASTRAZENECA AB (SE) | 2010-11-11 | — | — | US | claimed |
| EP-1966156-A2 | NEW COMPOUNDS III | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | claimed |
| US-20080171770-A1 | Compounds | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | claimed |
| WO-2007073303-A2 | NOVEL BENZIMIDAZOLE DERIVATIVES AS VANILLOID RECEPTOR 1 (VRL) INHIBITORS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | claimed |
| US-8168668-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-05-01 | — | — | US | disclosed |
| EP-1966156-B1 | NEW COMPOUNDS III | ASTRAZENECA AB (SE) | 2011-12-21 | — | — | EP | disclosed |
| US-20100286202-A1 | New Compounds | ASTRAZENECA AB (SE) | 2010-11-11 | — | — | US | disclosed |
| US-7618993-B2 | Compounds | ASTRAZENECA AB (SE) | 2009-11-17 | — | — | US | disclosed |
| EP-1966156-A2 | NEW COMPOUNDS III | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| US-20080171770-A1 | Compounds | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| WO-2007073303-A2 | NOVEL BENZIMIDAZOLE DERIVATIVES AS VANILLOID RECEPTOR 1 (VRL) INHIBITORS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286202-A1 | New Compounds | REN, PCSK9, FURIN | TRPV1 117/4885MAPK1 3756/4885GPR139 1736/4885 |
| US-20080171770-A1 | Compounds | REN, PCSK9, SLC10A1 | TRPV1 91/4885MAPK1 3790/4885GPR139 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.